|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM376815485 |
| 003 |
DE-627 |
| 005 |
20240828233229.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240828s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202409590
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1515.xml
|
| 035 |
|
|
|a (DE-627)NLM376815485
|
| 035 |
|
|
|a (NLM)39194369
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Qu, Liping
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 28.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Personalized cancer vaccines based on tumor cell lysates offer promise for cancer immunotherapy yet fail to elicit a robust therapeutic effect due to the weak immunogenicity of tumor antigens. Autophagosomes, obtained from pleural effusions and ascites of cancer patients, have been identified as abundant reservoirs of tumor neoantigens that exhibit heightened immunogenicity. However, their potential as personalized cancer vaccines have been constrained by suboptimal lymphatic-targeting performances and challenges in antigen-presenting cell endocytosis. Here,a reinforced biomimetic autophagosome-based (BAPs) nanovaccine generated by precisely amalgamating autophagosome-derived neoantigens and two types of adjuvants capable of targeting lymph nodes is developed to potently elicit antitumor immunity. The redox-responsive BAPs facilitate cytosolic vaccine opening within antigen-presenting cells, thereby exposing adjuvants and antigens to stimulate a strong immune response. BAPs evoke broad-spectrum T-cell responses, culminating in the effective eradication of 71.4% of established tumors. Notably, BAPs vaccination triggers enduring T-cell responses that confer robust protection, with 100% of mice shielded against tumor rechallenge and a significant reduction in tumor incidence by 87.5%. Furthermore, BAPs synergize with checkpoint blockade therapy to inhibit tumor growth in the poorly immunogenic breast cancer model. The biomimetic approach presents a powerful nanovaccine formula with high versatility for personalized cancer immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a antigen cross‐presentation
|
| 650 |
|
4 |
|a autophagosome
|
| 650 |
|
4 |
|a cancer vaccine
|
| 650 |
|
4 |
|a immunotherapy
|
| 650 |
|
4 |
|a lymphatic delivery
|
| 700 |
1 |
|
|a Cui, Guanhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Yinping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ye, Ruonan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meng, Fenghua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Shenqiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhong, Zhiyuan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2024) vom: 28. Aug., Seite e2409590
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g year:2024
|g day:28
|g month:08
|g pages:e2409590
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202409590
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2024
|b 28
|c 08
|h e2409590
|